BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting

Core Insights - BioNTech will present clinical trial data from its oncology portfolio at the ASCO Annual Meeting, showcasing progress in mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies [1][4] Group 1: Clinical Trial Highlights - The company is advancing over 20 active Phase 2 and 3 clinical trials, focusing on investigational mRNA cancer immunotherapies and the next-generation immunomodulator BNT327 [4] - BNT327, an investigational anti-PD-L1xVEGF-A antibody, will have three presentations detailing data from ongoing clinical trials, including a Phase 2 trial for malignant mesothelioma and Phase 3 trials for small cell lung cancer [5][8] - Data on BNT324/DB-1311, a B7H3-targeted ADC candidate, will be presented, indicating early clinical activity in heavily pre-treated castration-resistant prostate cancer [5][8] Group 2: Future Directions - BioNTech aims to become a diversified multi-product oncology company, with multiple data readouts expected in 2025 and 2026 [4] - The company emphasizes the potential of its assets to improve patient outcomes through innovative therapeutic modalities [2][4] - The presentations at ASCO are part of BioNTech's strategy to shape the future of cancer medicine through complementary mechanisms and innovative molecules [2]